Dr. David E. Stewart, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 Smithville Hwy Ste 114, Mc Minnville, TN 37110 Phone: 931-473-3183 Fax: 931-815-2491 |
Jan R Bratcher, DPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 835 Smithville Hwy, Mc Minnville, TN 37110 Phone: 931-473-9626 |
Charles Wallace Marsh Iii, DPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1500 Sparta St, Mc Minnville, TN 37110 Phone: 931-473-4471 Fax: 931-473-2217 |
Dr. Donna K. Carr, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1100 Smithville Hwy, Suite 114, Mc Minnville, TN 37110 Phone: 931-934-3282 Fax: 931-473-3183 |
Mr. James Whitley Taylor, D.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1500 Sparta St, Mc Minnville, TN 37110 Phone: 931-473-4471 Fax: 931-473-2217 |
Dr. Lea Taylor, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1500 Sparta St, Mc Minnville, TN 37110 Phone: 931-473-4471 |
Mrs. Melissa Beth Stanley, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1500 Sparta St, Mc Minnville, TN 37110 Phone: 931-473-4471 Fax: 931-473-2217 |
News Archive
Responding to a new study demonstrating the severity of the HIV epidemic among men who have sex with men (MSM) in low- and middle-income countries, amfAR, the Foundation for AIDS Research, called on policymakers to put aside their prejudices and to provide the resources and the leadership that the epidemic demands.
The mouth is widely considered the dirtiest part of the human body, yet babies have surprisingly low infection rates following cleft lip and palate surgery.
New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.
RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 191 fully-owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2010.
Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for disease targets accessible via the GI tract, announced today that it has been awarded a Phase I SBIR grant from the National Institute of Dental and Craniofacial Research to support the development of a novel antibody therapeutic for oral mucositis.
› Verified 9 days ago